Ivona Baricevic1, Xiaotong He2, Bipasha Chakrabarty3, Anthony W Oliver2, Charles Bailey4, Jeff Summers4, Lynne Hampson2, Ian Hampson2, Duncan C Gilbert5, Andrew G Renehan6. 1. Viral Oncology Group, Institute of Cancer Sciences, University of Manchester, Manchester, UK. 2. Viral Oncology Group, St Mary's Hospital, University of Manchester, Manchester, UK. 3. Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK. 4. Kent Oncology Centre, Maidstone and Tunbridge Wells Hospital, UK. 5. Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK. 6. Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. Electronic address: andrew.renehan@ics.manchester.ac.uk.
Abstract
BACKGROUND: Characterisation of human papilloma virus (HPV) infection in anal squamous cell carcinoma (ASCC) may have dual importance: first, aetiological; second, prognostic, informing outcome after chemo-radiotherapy (CRT). We undertook HPV genotyping, and allelic characterisations, to evaluate the aetiological role of HPV while simultaneously evaluating the impact of HPV genotyping on relapse-free (RFS) and overall survival (OS). METHOD: Dual-primer HPV genotyping (subtypes 6, 11, 16, 18, 31, 33, 45, 52, 58) and DNA sequencing of HPV 16 positive tumours were analysed in 151 consecutively referred ASCCs, previously characterised by immunohistochemistry for p16 expression. In 110 patients treated with CRT, factors influencing RFS and OS were evaluated using univariate and multivariate models. RESULTS: HPV positivity was observed in 95%. HPV 16 accounted for 89%; of these, 64% harboured the T350G E6 variant. HPV 16 positivity was significantly correlated with improved 5-year RFS (62% versus 40%; p = 0.027) and OS (59% versus 38%; p = 0.019). p16 expression was also significantly correlated with improved 5-year RFS (positive versus negative: 65% versus 16%; p < 0.0001) and OS (63% versus 13%; p < 0.0001). In multivariable models that included HPV 16 status, p16 status, sex, and age, p16 expression remained an independent prognostic factor for RFS (p < 0.0001) and OS (p = 0.002). CONCLUSION: In ASCC, near-universal HPV detection rates were demonstrated, higher than generally reported in the literature, and supporting the development of multivalent HPV vaccinations for prevention. By contrast, p16 negatively, but not HPV 16 genotype, is an independent adverse prognosticator after chemo-radiotherapy in patients with ASCC.
BACKGROUND: Characterisation of human papilloma virus (HPV) infection in anal squamous cell carcinoma (ASCC) may have dual importance: first, aetiological; second, prognostic, informing outcome after chemo-radiotherapy (CRT). We undertook HPV genotyping, and allelic characterisations, to evaluate the aetiological role of HPV while simultaneously evaluating the impact of HPV genotyping on relapse-free (RFS) and overall survival (OS). METHOD: Dual-primer HPV genotyping (subtypes 6, 11, 16, 18, 31, 33, 45, 52, 58) and DNA sequencing of HPV 16 positive tumours were analysed in 151 consecutively referred ASCCs, previously characterised by immunohistochemistry for p16 expression. In 110 patients treated with CRT, factors influencing RFS and OS were evaluated using univariate and multivariate models. RESULTS:HPV positivity was observed in 95%. HPV 16 accounted for 89%; of these, 64% harboured the T350G E6 variant. HPV 16 positivity was significantly correlated with improved 5-year RFS (62% versus 40%; p = 0.027) and OS (59% versus 38%; p = 0.019). p16 expression was also significantly correlated with improved 5-year RFS (positive versus negative: 65% versus 16%; p < 0.0001) and OS (63% versus 13%; p < 0.0001). In multivariable models that included HPV 16 status, p16 status, sex, and age, p16 expression remained an independent prognostic factor for RFS (p < 0.0001) and OS (p = 0.002). CONCLUSION: In ASCC, near-universal HPV detection rates were demonstrated, higher than generally reported in the literature, and supporting the development of multivalent HPV vaccinations for prevention. By contrast, p16 negatively, but not HPV 16 genotype, is an independent adverse prognosticator after chemo-radiotherapy in patients with ASCC.
Authors: Myeong-Kyun Shin; Susan Payne; Andrea Bilger; Kristina A Matkowskyj; Evie Carchman; Dominique S Meyer; Mohamed Bentires-Alj; Dustin A Deming; Paul F Lambert Journal: Clin Cancer Res Date: 2018-12-07 Impact factor: 13.801
Authors: James S Lewis; Lisa Mirabello; Ping Liu; Xiaowei Wang; William D Dupont; W Dale Plummer; Maisa Pinheiro; Meredith Yeager; Joseph F Boland; Michael Cullen; Mia Steinberg; Sara Bass; Mitra Mehrad; Connor O'Boyle; Maoxuan Lin; Daniel L Faden; Krystle A Lang-Kuhs Journal: Head Neck Pathol Date: 2021-04-02
Authors: Duncan C Gilbert; Eva Serup-Hansen; Dorte Linnemann; Estrid Høgdall; Charles Bailey; Jeff Summers; Hanne Havsteen; Gareth J Thomas Journal: Br J Cancer Date: 2016-01-05 Impact factor: 7.640
Authors: Rohit Kochhar; Andrew G Renehan; Damian Mullan; Bipasha Chakrabarty; Mark P Saunders; Bernadette M Carrington Journal: Eur Radiol Date: 2016-04-18 Impact factor: 5.315